Recent evidence demonstrates that glucose-lowering medications, such as glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter-2 inhibitors, are of particular benefit in the prevention and treatment of CKD in patients with type 2 diabetes [36]. Here, GLP1R is linked to chronic kidney disease.